Literature DB >> 12028458

Outcome of relapse in lupus nephritis: roles of reversal of renal fibrosis and response of inflammation to therapy.

Gary S Hill1, Michel Delahousse, Dominique Nochy, Eric Thervet, François Vrtovsnik, Philippe Rémy, Denis Glotz, Jean Bariéty.   

Abstract

BACKGROUND: Renal relapse in lupus nephritis has been shown to have ominous prognostic significance with the majority of patients progressing to doubling of serum creatinine (CRX2). However, not all patients do so. This report explores the roles of response of inflammation to therapy and of glomerular scarring and interstitial fibrosis and their potential reversal to outcome of renal relapse.
METHODS: Renal biopsies from 71 patients with lupus nephritis with an initial biopsy (Bx1) and systematic control biopsy (Bx2) after six months of therapy, as well as subsequent biopsies for clinical indications, were studied. The relationships of morphologic factors to renal relapse and its outcome as well as to CRX2 and end-stage renal disease (ESRD) were analyzed. Cox proportional hazards modeling was used to assess association of morphologic variables with outcomes.
RESULTS: Renal interstitial fibrosis and glomerular segmental scarring were partially reversible in 17 and 11 patients, respectively. This decline was associated with an excellent prognosis, with only one patient in each group (5.9% and 9.1% respectively) progressing to CRX2. All 18 patients who progressed to CRX2 either failed to respond to therapy (7 patients) as defined by normalization of serum creatinine (SCr) and reduction of proteinuria to < or =1 g/day, or relapsed after initial response (11 patients), as defined by recent rise of SCr > 50% and/or proteinuria > 3.5 g/day. However, relapse also occurred in 11 of 47 other patients without progression to CRX2. These patients showed a greater initial response of inflammation and deposits to therapy and fibrous lesions partially reversed in the period prior to relapse, so that active lesions were superimposed on a lower level of chronic lesions. By contrast, chronic lesions mounted steadily in those who progressed to CRX2. Cox proportional hazards modeling indicated a strong association of inflammatory variables with renal relapse, CRX2 and ESRD. However, the extent of immunoglobulin deposits was not significantly associated with any outcome. Finally, we found that failure of disease to remit also is associated with a high rate of CRX2 (64.8% vs. 13.0%, P = 0.00034).
CONCLUSIONS: Interstitial fibrosis and glomerular scarring in systemic lupus erythematosus are partially reversible, and this reversal is attended by an excellent outcome. The outcome of renal relapse is determined by the initial response of inflammatory and chronicity elements to therapy, those with prior partial reversal of interstitial and glomerular scarring having a good outcome, and those in whom fibrotic lesions have continued to increase and have a poor outcome. Inflammatory variables appear to be more important in determining outcome than immunoglobulin deposits.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12028458     DOI: 10.1046/j.1523-1755.2002.00357.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  21 in total

1.  Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis.

Authors:  Celine C Berthier; Ramalingam Bethunaickan; Tania Gonzalez-Rivera; Viji Nair; Meera Ramanujam; Weijia Zhang; Erwin P Bottinger; Stephan Segerer; Maja Lindenmeyer; Clemens D Cohen; Anne Davidson; Matthias Kretzler
Journal:  J Immunol       Date:  2012-06-20       Impact factor: 5.422

2.  A critical role of the transcription factor fli-1 in murine lupus development by regulation of interleukin-6 expression.

Authors:  Shuzo Sato; Mara Lennard Richard; Danielle Brandon; Joy N Jones Buie; Jim C Oates; Gary S Gilkeson; Xian K Zhang
Journal:  Arthritis Rheumatol       Date:  2014-12       Impact factor: 10.995

3.  IL-34-Dependent Intrarenal and Systemic Mechanisms Promote Lupus Nephritis in MRL-Faslpr Mice.

Authors:  Yukihiro Wada; Hilda M Gonzalez-Sanchez; Julia Weinmann-Menke; Yasunori Iwata; Amrendra K Ajay; Myriam Meineck; Vicki R Kelley
Journal:  J Am Soc Nephrol       Date:  2019-01-08       Impact factor: 10.121

Review 4.  B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data.

Authors:  R John Looney
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

5.  Comparison of clinical, serological, and prognostic differences among juvenile-, adult-, and late-onset lupus nephritis in Korean patients.

Authors:  Ji-Hyoun Kang; Dong-Jin Park; Kyung-Eun Lee; Ji Shin Lee; Yoo-Duk Choi; Shin-Seok Lee
Journal:  Clin Rheumatol       Date:  2017-04-25       Impact factor: 2.980

6.  Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo.

Authors:  Nicole L Regna; Cristen B Chafin; Sarah E Hammond; Abdul G Puthiyaveetil; David L Caudell; Christopher M Reilly
Journal:  Clin Immunol       Date:  2014-01-15       Impact factor: 3.969

Review 7.  Diagnosis and treatment of lupus nephritis flares--an update.

Authors:  Ben Sprangers; Marianne Monahan; Gerald B Appel
Journal:  Nat Rev Nephrol       Date:  2012-11-13       Impact factor: 28.314

8.  Clinical and Histopathologic Characteristics Associated with Renal Outcomes in Lupus Nephritis.

Authors:  Emilie C Rijnink; Y K Onno Teng; Suzanne Wilhelmus; Mathilde Almekinders; Ron Wolterbeek; Karlien Cransberg; Jan A Bruijn; Ingeborg M Bajema
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-04       Impact factor: 8.237

9.  Dual roles of immunoregulatory cytokine TGF-beta in the pathogenesis of autoimmunity-mediated organ damage.

Authors:  Vijay Saxena; Douglas W Lienesch; Min Zhou; Ramireddy Bommireddy; Mohamad Azhar; Thomas Doetschman; Ram Raj Singh
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

10.  Connective tissue growth factor gene expression and decline in renal function in lupus nephritis.

Authors:  Chiraporn Tachaudomdach; Surasak Kantachuvesiri; Siribha Changsirikulchai; Surangkana Wimolluck; Koset Pinpradap; Chagriya Kitiyakara
Journal:  Exp Ther Med       Date:  2012-02-03       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.